Ovarian Cancer
1434 clinical trials
261 cell line models
14 approved drugs
Ovarian Cancer
Molecular Synopsis
Drugs and clinical candidates

14 drugs have received FDA approval for Ovarian Cancer:

  • Amifostine
  • Bevacizumab
  • Carboplatin
  • Cisplatin
  • Cyclophosphamide

268 drugs have a clinical trial registered for Ovarian Cancer.

5988 compounds have been tested in Ovarian Cancer (4059 <= 500nM potency).

Sources: cancer.gov, clinicaltrials.gov, ChEMBL.

Clinical trials
There are 1434 clinical trials for Ovarian Cancer, 866 of which have one or more drug interventions, 568 with no drug intervention.
Cell line models

There are 261 Cell Line Models for Ovarian Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Ovarian Cancer:
  • Hereditary Breast and Ovarian Cancer Syndrome
  • Krukenberg Tumor
  • Brenner Tumor
  • Carcinoma, Ovarian Epithelial
  • Ovarian Neoplasms
The following terms have been mapped from cancer.gov to Ovarian Cancer:
  • Ovarian cancer that has certain germline mutations in the BRCA1 or BRCA2 gene and is advanced. It is used in adults who have already been treated with at least three other types of chemotherapy
  • Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used:As maintenance therapy in adults with recurrent disease who are having a complete or partial response to platinum chemotherapy
  • Ovarian cancer that is advanced. It is used with other chemotherapy as first-line treatment. It is used alone as palliative treatment for disease that has recurred (come back) after earlier chemotherapy
  • Ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is used in patients with stage III, stage IV, or recurrent disease. This use is approved for the Avastin brand of bevacizumab
  • Ovarian cancer that has gotten worse or recurred (come back) after treatment with other chemotherapy